These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2522006)

  • 21. [Regression of left heart hypertrophy in arterial hypertension: principles, experimental and clinical findings].
    Klaus D
    Z Kardiol; 1985; 74 Suppl 7():153-69. PubMed ID: 2936016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of antihypertensive pharmacologic treatment in countering adverse pathophysiological profiles: influence on small arteries.
    Dahlöf B
    Am Heart J; 1987 Oct; 114(4 Pt 2):984-91. PubMed ID: 3661387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of cardiac hypertrophy by medical treatment.
    Tarazi RC; Fouad FM
    Annu Rev Med; 1985; 36():407-14. PubMed ID: 3158269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Methods for studying vasodilator agents in arterial hypertension].
    Laurent S; Asmar R; Pannier B; London G; Safar M
    Arch Mal Coeur Vaiss; 1990 Mar; 83 Spec No 2():69-73. PubMed ID: 2140502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the decrease in arterial pressure the sole factor for reduction of left ventricular hypertrophy?
    Schmieder RE; Messerli FH
    Am J Med; 1992 Apr; 92(4B):28S-34S. PubMed ID: 1533746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression of left ventricular mass in systemic hypertension.
    Georgiou D; Brundage BH
    Clin Cardiol; 1992 Jan; 15(1):5-16. PubMed ID: 1531790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Regression of biochemical changes in heart muscle hypertrophy].
    Zähringer J
    Z Kardiol; 1985; 74 Suppl 7():119-26. PubMed ID: 2868582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The development of coronary insufficiency during prolonged treatment of essential hypertension.
    Kalnins UV; Skarda IJ; Liepinja DJ; Vitols AV
    Cor Vasa; 1990; 32(1):64-71. PubMed ID: 2140319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [An evaluation of the therapeutic trials aimed at regression of ventricular hypertrophy in arterial hypertension].
    Clémenty J; Dulhoste MN; Bordier P; Lartigue MC; Pons N
    Ann Cardiol Angeiol (Paris); 1991 Oct; 40(8):503-8. PubMed ID: 1836942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective and prospective research on hypertension-related end-organ damage.
    Perloff D
    J Cardiovasc Pharmacol; 1994; 24 Suppl A():S1-5. PubMed ID: 7603071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The primary and secondary prevention of hypertensive cardiopathy].
    Agabiti-Rosei E; Muiesan ML
    Ital Heart J; 2000 Jun; 1 Suppl 2():59-66. PubMed ID: 10905130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Coronary microangiopathy in hypertensive heart disease: pathogenesis, diagnosis and therapy].
    Motz W; Scheler S; Strauer BE
    Herz; 1995 Dec; 20(6):355-64. PubMed ID: 8582695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of left ventricular hypertrophy following treatment of hypertension with isradipine.
    Saragoça MA; Portela JE; Abreu P; Plavnik F; Ventura R; Vanneta A; Ajzen H; Ramos OL
    J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S28-30. PubMed ID: 1720481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arterial dynamics, cardiac hypertrophy, and antihypertensive treatment.
    Safar ME; Toto-Moukouo JJ; Bouthier JA; Asmar RE; Levenson JA; Simon AC; London GM
    Circulation; 1987 Jan; 75(1 Pt 2):I156-61. PubMed ID: 2947747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drugs and arterial stiffness in hypertensive patients].
    Laurent S
    Drugs; 2003; 63 Spec No 1():1-8. PubMed ID: 12708878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.